CASC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CASC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Cascadian Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cascadian Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | |||||||||||
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | - | - | - | - | - |
Cascadian Therapeutics Quarterly Data | ||||||||||||||||||||
Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Cascadian Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cascadian Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Cascadian Therapeutics's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Cascadian Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2017 is calculated as:
For example, Cascadian Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2017 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2017 (Change) | * | Current CPI (Dec. 2017) |
= | -0.244 | / | 104.0111 | * | 104.0111 | |
= | -0.244 |
Current CPI (Dec. 2017) = 104.0111.
Cascadian Therapeutics Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
200803 | -2.343 | 90.090 | -2.705 |
200806 | -0.755 | 92.320 | -0.851 |
200809 | -0.867 | 92.307 | -0.977 |
200812 | 2.196 | 88.697 | 2.575 |
200903 | -1.150 | 89.744 | -1.333 |
200906 | -0.810 | 91.003 | -0.926 |
200909 | -0.442 | 91.120 | -0.505 |
200912 | -0.503 | 91.111 | -0.574 |
201003 | -1.024 | 91.821 | -1.160 |
201006 | -1.405 | 91.962 | -1.589 |
201009 | -0.701 | 92.162 | -0.791 |
201012 | -0.901 | 92.474 | -1.013 |
201103 | -0.930 | 94.283 | -1.026 |
201106 | -0.836 | 95.235 | -0.913 |
201109 | -0.902 | 95.727 | -0.980 |
201112 | -0.656 | 95.213 | -0.717 |
201203 | -0.925 | 96.783 | -0.994 |
201206 | -0.716 | 96.819 | -0.769 |
201209 | -0.634 | 97.633 | -0.675 |
201212 | -0.760 | 96.871 | -0.816 |
201303 | -0.708 | 98.209 | -0.750 |
201306 | -1.722 | 98.518 | -1.818 |
201309 | -0.676 | 98.790 | -0.712 |
201312 | -0.477 | 98.326 | -0.505 |
201403 | -0.689 | 99.695 | -0.719 |
201406 | -0.489 | 100.560 | -0.506 |
201409 | -0.577 | 100.428 | -0.598 |
201412 | -1.796 | 99.070 | -1.886 |
201503 | -0.521 | 99.621 | -0.544 |
201506 | -0.460 | 100.684 | -0.475 |
201509 | -0.394 | 100.392 | -0.408 |
201512 | -0.458 | 99.792 | -0.477 |
201603 | -0.621 | 100.470 | -0.643 |
201606 | -0.555 | 101.688 | -0.568 |
201609 | -0.415 | 101.861 | -0.424 |
201612 | -0.388 | 101.863 | -0.396 |
201703 | -0.351 | 102.862 | -0.355 |
201706 | -0.218 | 103.349 | -0.219 |
201709 | -0.247 | 104.136 | -0.247 |
201712 | -0.244 | 104.011 | -0.244 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Cascadian Therapeutics (NAS:CASC) Cyclically Adjusted Price-to-FCF Explanation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Cascadian Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Ted W Love | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Gwen A. Fyfe | director | C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301 |
Steven P James | director | C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
Julia Marie Eastland | officer: CFO & CBO | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Christopher S Henney | director | 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
Robert Azelby | director | 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
Daniel K Spiegelman | director | MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003 |
Scott Dunseth Myers | director, officer: President and CEO | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Growth Equity Opportunities Iv, Llc | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Nea 15 Gp, Llc | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Nea Partners 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
New Enterprise Associates 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Jon Sakoda | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Florence Anthony A. Jr. | 10 percent owner | 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815 |
Peter W. Sonsini | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
From GuruFocus
By Holly LaFon Holly LaFon • 07-12-2016
By Kyle Ferguson Kyle Ferguson • 07-11-2016
By Henniker82 Henniker82 • 03-05-2013
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.